Dr. Bestvina is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S. MARYLAND AVE.
M/C 2115
Chicago, IL 60637Phone+1 773-702-4400Fax+1 773-702-0963
Education & Training
Duke University HospitalResidency, Internal Medicine, 2012 - 2015
Perelman School of Medicine at the University of PennsylvaniaClass of 2012
Certifications & Licensure
IL State Medical License 2015 - 2026
NC State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Start of enrollment: 2019 Jun 27
- M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 16
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Start of enrollment: 2019 Sep 19
- Join now to see all
Publications & Presentations
PubMed
- 137 citationsPatient-Oncologist Cost Communication, Financial Distress, and Medication AdherenceChristine M. Bestvina, Leah L. Zullig, Christel Rushing, Fumiko Chino, Gregory P. Samsa
Journal of Oncology Practice. 2014-05-01 - 1 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01 - 16 citationsSotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.Yasutoshi Kuboki, Marwan Fakih, John Strickler, Rona Yaeger, Toshiki Masuishi
Nature Medicine. 2024-01-01
Press Mentions
ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022- Combining Immune Checkpoint and VEGF Inhibitors Improves Survival in Pretreated NSCLCJune 4th, 2022
- Oncogene-Specific Advocacy Groups Bring a Patient-Centric Perspective to Studies of Lung CancerNovember 18th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
